Shares of the two drug makers discussed in today’s article have been beaten down, thanks in large part to an FDA advisory panel vote in… Read More »Are These 2 Beaten-Down Biotechs Buys Before Bouncing Back?
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s… Read More »“Sizable Upside Potential”: 5 Low-Priced Stocks For Highly Aggressive Investors
If you want to pick your own biotech stocks, rather than investing in a biotech-focused ETF or mutual fund, the author of today’s article advises… Read More »Biotech Bargains: 4 Names Trading Far Below Their Average Price Targets
As the unofficial winner of the COVID-19 vaccine race (along with partner Pfizer), BioNTech can be considered the No. 1 biotech stock. But the German… Read More »How The “No. 1 Biotech Stock” Is Expanding Its Footprint In The U.S.
The rapid spread of the hyper-contagious Delta variant of the coronavirus, along with the increasing need for treatments for other critical diseases, ensures a continued… Read More »3 Biotech Stocks With Promising Product Pipelines And More Than 170% Near-Term Upside Potential
Industry analysts expect M&A activity in the biotech space to accelerate in the back half of 2021 – and that could drive the ETF highlighted… Read More »This Biotech ETF Is “Prime Hunting Ground” For Big Pharma Companies Looking For Takeover Targets
Against the current backdrop for the biotech industry, comprised of continued efforts to fight COVID-19 as well as a focus on developing treatments for heretofore… Read More »These 2 Biotech Stocks Appear Attractively Cheap And Attractively Positioned For Solid Returns
With his Perceptive Advisors hedge fund, which specializes in taking big positions in small-cap biotech stocks, billionaire Joseph Edelman has proven himself to be one… Read More »A Biotech Billionaire Has Taken Big Positions In These Small Stocks
Looking at the biotech sector right now, new drug approvals could gain momentum in the wake of the FDA’s approval of Biogen’s Alzheimer’s drug, mergers… Read More »3 Outperforming Biotech Stocks With Further Upside In The Back Half Of 2021